ArticleTransplantation and cellular therapy2026
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.Bone marrow transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
Conflicting reports exist regarding the impact of extramedullary disease (EMD) at diagnosis upon outcomes after allogeneic hematopoietic cell transplantation (HCT) in children and young adults with acute myeloid leukemia (AML). We retrospectively analyzed the effect of EMD at diagnosis on post-HCT outcomes in a large cohort of children and young adults (21 and younger) who had AML and received their first myeloablative allogeneic HCT for AML during 2008 to 2019 (N = 938; 52% males). Data were obtained from the Center for International Blood and Marrow Transplant Research database. Patients were grouped based on EMD at diagnosis as bone marrow (BM) involvement only (Group I; n = 630); BM + central nervous system (CNS) involvement (Group II; n = 212), and BM + other EMD ± CNS (Group III n = 96). All patients were in a morphologic complete remission (CR) with no evidence of EMD pre-HCT. Outcomes compared included 3-yr progression-free survival (PFS), overall survival (OS), non-relapse mortality (NRM), and relapse incidence (RI). Group III patients were younger at HCT (Group III median age 3, versus age 11 in Group I, and age 10 in Group II) and more often had high Pediatric Disease Risk Index scores (52% in Group III versus 22% in Group I and 25% in Group II). At a median follow-up of 70 mo (range 3-155 mo), the 1-yr and 3-yr PFS, NRM, RI, and OS were similar among all 3 groups on univariate analysis. On multivariable analysis, the presence of EMD was associated with decreased RI: Group II, with a hazard ratio (HR) of 0.70 (95% CI, 0.52-0.94; P = .020) and Group III with an HR of 0.70 (95% CI, 0.46-1.05; P = .086) compared to Group I. There was no difference in PFS (P = .21), NRM (P = .27), and OS (P = .82) among the groups. In our study, in patients with AML who proceeded to HCT in CR, the presence of EMD at diagnosis was not associated with adverse outcomes or increased relapse risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.